Brief: Jasper Therapeutics To Present New Positive Data On Briquilimab Conditioning
21/09/2023 13:17
Sept 21 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS TO PRESENT NEW POSITIVE DATA ON
BRIQUILIMAB
CONDITIONING IN PATIENTS WITH FANCONI ANEMIA AT 2023 FANCONI
ANEMIA RESEARCH FUND SCIENTIFIC SYMPOSIUM
* JASPER THERAPEUTICS INC - BRIQUILIMAB WAS WELL TOLERATED
WITHOUT
ANY COMPLICATIONS
* JASPER THERAPEUTICS INC - STUDY EXPANSION TO PHASE 2A IS
ONGOING
* JASPER THERAPEUTICS INC - ALL THREE FANCONI ANEMIA
PATIENTS
TREATED WITH BRIQUILIMAB ACHIEVED FULL DONOR ENGRAFTMENT AND
FULL BLOOD COUNT RECOVERY
Source text for Eikon: ID:nGNX7V02LT
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma